The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Cited by
Sorted by citations
Items 801–900 of 1,000
EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects
Wirges, A., Bunse, M., Joedicke, J. J., Blanc, E., Gudipati, V., Moles, M. W., Shiku, H., Beule, D., Huppa, J. B., Höpken, U. E., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.009 · Cited by 7
Chen, Y., Zhao, H., Luo, J., Liao, Y., Dan, X., Hu, G., & Gu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944511 · Cited by 5
The Potential Role of Immunotherapy in Wilms’ Tumor: Opportunities and Challenges
Sanatkar, S. A., Heidari, A., Arya, S., Ghasemi, M., & Rezaei, N. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230721122011 · Cited by 5
Rafaniello, C., Liguori, V., Zinzi, A., Gaio, M., Falco, A., Costanzo, L. D., Gargano, F., Trimarco, V., Cataldi, M., & Capuano, A. (2023) · Biomedicines · doi:10.3390/biomedicines11082162 · Cited by 5
Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time
Odak, I., Bayir, L. M., Riemann, L., Sikora, R., Schneider, J., Xiao, Y., Möhn, N., Skripuletz, T., Beutel, G., Eder, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1298598 · Cited by 5
Khawaji, Z. Y., Khawaji, N., Alahmadi, M. A., & Elmoneim, A. A. A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01237-w · Cited by 5
Shams, F., Sharif, E., Abbasi‐Kenarsari, H., Hashemi, N., Hosseini, M. S., Heidari, N., Noori, E., Amini, A. H., Bazrgar, M., Rouhani, M., et al. (2025) · Current Gene Therapy · doi:10.2174/0115665232357078250331180413 · Cited by 6
Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL
Ghorashian, S., Amrolia, P. J., & Veys, P. A. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.07.002 · Cited by 5
The acceleration of CAR‐T therapy in non‐Hodgkin lymphoma
Munshi, P. N., & Ujjani, C. S. (2018) · Hematological Oncology · doi:10.1002/hon.2568 · Cited by 6
Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy
Chaudhry, K., Dowlati, E. P., & Bollard, C. M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1911648 · Cited by 5
Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
He, J., Xu, N., Zhou, H., Zhou, Y., Wu, D., Zhao, R., Lin, T., Xu, J., Cao, R., Li, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893928 · Cited by 5
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy
Zaki, A. A., McCurry, D., & Strati, P. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2185090 · Cited by 5
Kurnik, M., Peter, F., & Podbregar, M. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2370180 · Cited by 5
Myelopoiesis of acute inflammation: lessons from TGN1412-induced cytokine storm
Panoskaltsis, N., McCarthy, N. E., & Knight, S. C. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02702-9 · Cited by 5
PANoptosis in Cytokine Release Syndrome: Bridging the Gap between Inflammation and Cell Death
Eltaib, L., Alanazi, M. N., Khan, Y., Hanbashi, A., Khan, G., Rikabi, H. A., Maqbool, M., & Hussain, M. S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128404910250912133524 · Cited by 5
Chen, P., Raghunandan, R., Morrow, J. S., & Katz, S. G. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.04.002 · Cited by 5
Acute Kidney Injury Associated with Novel Anticancer Therapies
Karam, S., Ali, A., Fung, W. W., Mehta, P., Nair, S., & Anandh, U. (2025) · Kidney360 · doi:10.34067/kid.0000000749 · Cited by 4
Wang, Y., Gu, J., Chen, G., Jiang, Y., Xu, Y., Huang, X., Sun, W., & Gan, J. (2025) · Virology Journal · doi:10.1186/s12985-025-02868-7 · Cited by 5
Next generation CAR-T cells to tackle solid tumors
Abreu, T. R., Godinho‐Santos, A., Amaral, A. T., Paiva, A. A., Moreira, J. N., & Gonçalves, J. R. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114650 · Cited by 5
DNA-directed assembly of multivalent lipid nanoparticles for targeted T cell gene delivery
Kelly, M. D., Vu, T. Q., Iyer, A., Luo, Y., Linderman, A. P., Cline, L., Sanchez, C., & Kamat, N. P. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114885 · Cited by 4
CAR‐T Cells: Current Status, Challenges, and Future Prospects
Adly, A. S., Cartron, G., Adly, A. S., Egea, J., Dutilleul, P. C., Adly, M. S., & Villalba, M. (2026) · MedComm · doi:10.1002/mco2.70606 · Cited by 4
The role of podoplanin inhibitors in controlling oral cancer progression
Sayuddin, E. N. E. N., Taher, M., Arzmi, M. H., Burhanudin, N. A., & Rostam, M. A. (2023) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2023.105841 · Cited by 4
Important Considerations in the Intensive Care Management of Acute Leukemias
Pourhassan, H., Kareem, W., Agrawal, V., & Aldoss, I. T. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231193955 · Cited by 4
Kurtz, D. A., Sharma, A., Sharma, A., & Soubani, A. O. (2024) · Journal of Intensive Care Medicine · doi:10.1177/08850666241253537 · Cited by 4
Newman, M. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462221 · Cited by 4
Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy
Barjasteh, A. H., Saebi, M., Mahmoudi, M., Kheder, R. K., Hashemy, S. I., Forouzanfar, F., & Esmaeili, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128336391241107112957 · Cited by 4
Hematologic and Non-CRS Toxicities
Ceppi, F., Summers, C. N., & Gardner, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00008-1 · Cited by 4
Practical aspects of building a new immunotherapy program: the future of cell therapy
Berdeja, J. G. (2020) · Hematology · doi:10.1182/hematology.2020000144 · Cited by 5
Shi, X., & Wu, H. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221078727 · Cited by 4
Roman, C. M., Sakemura, R. L., Jin, F., Khadka, R. H., Adada, M. M., Siegler, E. L., Johnson, A. J., & Kenderian, S. S. (2023) · Journal of Visualized Experiments · doi:10.3791/64535 · Cited by 4
Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia
Agrawal, V., Murphy, L. A., Pourhassan, H., Pullarkat, V. A., & Aldoss, I. T. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14109 · Cited by 4
Chen, H.-H., Kuo, C., Ho, C., & Chen, Y. (2023) · Medicine · doi:10.1097/md.0000000000035432 · Cited by 4
Ligon, J. A., Ramakrishna, S., Ceppi, F., Calkoen, F., Diorio, C. J., Davis, K. L., Jacoby, E., Gottschalk, S. M., Schultz, L. M., & Capitini, C. M. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.012 · Cited by 4
A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist
Ong, S. Y., & Baird, J. H. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231205264 · Cited by 5
Yoshida, M., Matsuoka, Y., Mitsuyuki, S., Yonetani, N., Kawai, J., Kondo, T., & Ishikawa, T. (2023) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2023-021 · Cited by 4
He, C. X., Xue, L., Qiang, P., Xu, H., Zhang, X. H., Liu, X., Zhu, W., Cai, X., Liu, H.-C., Sun, Z., et al. (2020) · PubMed · doi:10.3760/cma.j.issn.0253-2727.2020.06.010 · Cited by 4
Single-cell technologies to dissect heterogenous immune cell therapy products
Mueller, K. P., & Saha, K. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100343 · Cited by 4
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products
Karmali, R. (2021) · Hematology · doi:10.1182/hematology.2021000249 · Cited by 4
Ma, Y., Zhang, H., Dou, L., Sun, H., Yu, J., Gu, Z., Wang, L., & Gao, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114577 · Cited by 3
STING regulates NETs formation by activating GSDMD in influenza viral pneumonia
Huang, R., Chen, R., Xing, L., Wu, L., Zhu, W., Jing, J., Zhou, T., Wu, Y., Zhang, S., & You, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1598902 · Cited by 3
Naik, S., Selukar, S., Talleur, A. C., Deshpande, S., Llaurador, G., Fabrizio, V. A., Rouce, R. H., Zeng, X. L., Vatsayan, A., Rossoff, J. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016824 · Cited by 3
Cytokine release syndrome risk model with T-cell engaging therapies
Lafeuille, P., Blumentals, W. A., Brulle-Wohlhueter, C., Chen, W., Sang, C., Manning, S. E., Saltzman, S., Canvin, J., Richards, S. M., Kamperschroer, C., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.07.002 · Cited by 3
Self-citationWobma, H., Henderson, L. A., Duncan, C., Prockop, S. E., Randolph, A. G., Degar, B. A., Lehmann, L., & Baumeister, S. H. C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1631557 · Cited by 3
The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy
Stewart, C. M., Siegler, E. L., & Kenderian, S. S. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0631 · Cited by 3
Fettiplace, A., Regev, A., Kiazand, A., Heinzel-Pleines, U., Bahjat, M., Garg, A., Kikuchi, L., Li, H., Hamidi, A., Alpers, D., et al. (2025) · Drug Safety · doi:10.1007/s40264-025-01635-5 · Cited by 3
Scheller, L., Zhou, X., Loeffler‐Wirth, H., Kreuz, M., Kadel, S., Schimanski, S., Schulze, H., Ruckdeschel, A. M., Eisele, F., Konetzki, V., et al. (2025) · HemaSphere · doi:10.1002/hem3.70267 · Cited by 3
CAR ‐T cell therapy: Advancements in clinical applications and laboratory testing
Nam, M., & Lee, J. (2026) · International Journal of Cancer · doi:10.1002/ijc.70348 · Cited by 3
The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL)
Sharplin, K. M., & Marks, D. I. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2020780 · Cited by 3
Zhao, K., Sun, J., He, M., Ruan, H., Lin, G., & Shen, N. (2023) · Cancer Nursing · doi:10.1097/ncc.0000000000001275 · Cited by 3
Zou, B., Song, Y.-Z., Li, N., Fan, Z., Li, J., Peng, Y., Wei, W., Zhang, Y., Su, Y., Meng, X., et al. (2024) · iLABMED · doi:10.1002/ila2.31 · Cited by 3
CAR T-cell therapy and the onco-nephrologist
Salvino, M., Mussetti, A., Peña, M., Paviglianiti, A., Carreira, A., Rizky, D., & Sureda, A. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2024.1378250 · Cited by 4
CAR-T Cells: A Breakthrough in Cancer Treatment
Sriwastava, A., Gupta, S., Kumar, A., Gupta, S., & Kumar, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005110 · Cited by 3
Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects
Zhang, K., Zhang, Y., Pan, X., Wang, Y., Li, Y., Jiang, S., Zhang, Y., Chen, M., Su, W., Li, X., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01502 · Cited by 3
Si, C., Li, Y., Wang, Y., Gao, J., & Ma, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167890 · Cited by 3
Qiao, Y., Han, Y., Zhao, L., Gao, W., Hu, H., Su, C., Zheng, A., Sun, J., Tian, M., Wu, Y., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00320-4 · Cited by 3
Islam, J., Rashid, Z., Munster, A. B., Hughes, P., Badžek, S., & Huda, I. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01336-3 · Cited by 3
Imakita, T., Fujita, K., Yamamoto, Y., Kanai, O., Okada, Y., Toyama, S., Ito, T., Oi, I., & Tanizawa, K. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04243-5 · Cited by 3
Holzinger, A., & Abken, H. (2017) · InTech eBooks · doi:10.5772/66496 · Cited by 3
Genetically modified immune cells for cancer immunotherapy
Jiang, L., & Wang, W. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9395-0 · Cited by 3
Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care
Khazal, S. J., & Mahadeo, K. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_200 · Cited by 3
Lai, X., Sun, Y., Chang, L. J., Ma, Y. R., Gu, X. Z., Yao, X. M., Nie, B., Wen, Y., Zhang, X. M., Jiang, Y. X., et al. (2020) · Bioengineered · doi:10.1080/21655979.2020.1791597 · Cited by 3
Whole-process management of complications during CAR-T therapy
Li, Y., & Mei, H. (2022) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0005 · Cited by 4
Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management
Romano, J., Wilsterman, E. J., Toal, M., & Joyce, C. L. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2022.09.004 · Cited by 3
Arcila, M. E., Patel, U., Boroujeni, A. M., Yao, J., Chan, R., Chan, J., Rijo, I., Yu, W., Chaves, N., Patel, H., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.06.002 · Cited by 3
Xiong, Z.-Y., Shen, Y., Zhang, S., & Zhu, H. (2024) · Hematology · doi:10.1080/16078454.2024.2335856 · Cited by 3
Tatake, I. J., & Arnason, J. E. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101601 · Cited by 3
Nardone, V., Ruggiero, D., Chini, M. G., Bruno, I., Lauro, G., Terracciano, S., Nebbioso, A., Bifulco, G., Cappabianca, S., & Reginelli, A. (2025) · Cancers · doi:10.3390/cancers17071059 · Cited by 3
Rapid Determination of Iron in Serum and Plasma Using Micromagnetic Resonance Relaxometry (μMRR)
Yang, Y., Zen, N. T. K., Kang, M., Chen, M., Liang, C., Lim, F. W. I., Chen, Y., Zeming, K. K., & Han, J. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05735 · Cited by 3
Justiz-Vaillant, A. A., Soodeen, S., Gopaul, D., Arozarena-Fundora, R., & Akpaka, P. E. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.1931159 · Cited by 3
Adkins, S. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.8.5 · Cited by 3
Dave, P., Vela, E. P., & Cancarevic, I. (2021) · Cureus · doi:10.7759/cureus.17709 · Cited by 3
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
Nath, K., Wudhikarn, K., Tomás, A. A., & Perales, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2177268 · Cited by 3
An updated overview of the application of CAR‐T cell therapy in neurological diseases
Shahabifard, H., Zarei, M., Kookli, K., Afyouni, N. E., Soltani, N., Maghsoodi, S., Adili, A., Mahmoudi, J., Shomali, N., & Shotorbani, S. S. (2023) · Biotechnology Progress · doi:10.1002/btpr.3356 · Cited by 3
Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022
Shen, J., Li, J., Lei, Y., Chen, Z., Wu, L., & Lin, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30955 · Cited by 3
Napolitano, S., Ottaviano, G., Bettini, L. R., Russotto, V., Bonanomi, S., Rovelli, A., Biondi, A., Rona, R., & Balduzzi, A. (2021) · Tumori Journal · doi:10.1177/03008916211053382 · Cited by 3
Immunotherapy as an emerging and promising tool against viral infections
Askari, V. R., Yahyazadeh, R., & Rahimi, V. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00004-0 · Cited by 3
Potential regulation of NF-κB by Curcumin in Coronavirus-induced cytokine storm and lung injury
Motaghinejad, M., Gholami, M., Adibipour, F., Valipour, S., & Ulloa, L. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_565_20 · Cited by 3
Cytokine release syndrome. Reviewing a new entity in the intensive care unit
García‐Roche, A., Lagares, C. D., Élez, E., & Ferrer, R. (2019) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2019.01.011 · Cited by 3
Cytokines in hematopoietic cell transplantation and related cellular therapies
Bazarbachi, A. H., & Mapara, M. Y. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101600 · Cited by 2
CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses
Nguyen, K. A., Liu, Z., Davies, J. S., McIntosh, C. P., Draper, L. M., Norberg, S. M., Rae, Z., Achar, S. R., Altan-Bonnet, G. Y., Zhang, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq4297 · Cited by 4
Kubick, N., Łazarczyk, M., Awad, O., Ławiński, M., Horbańczuk, J. O., Sacharczuk, M., Atanasov, A. G., Religa, P., & Mickael, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050381 · Cited by 2
Sun, P., Cui, C., Zhao, B., Zhang, B., Yang, H., Yu, Z., Xu, F., Huang, K.-M., Liu, Y.-T., Ouyang, M., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04080-6 · Cited by 2
Rosenberg, M. C., Scarpetti, L., Morgan, G. J., & Davies, F. E. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.013 · Cited by 2
Mayor-Vázquez, E., Fito, E. C., Marcos-Neira, P., Díaz‐Lagares, C., Gomila-Sintes, C., Albala, N., García‐Roche, A., & Castro, P. (2025) · Medicina Intensiva · doi:10.1016/j.medin.2025.502254 · Cited by 2
A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity
Chen, Y., Wang, P., Yang, M., Lu, H., Lu, Q., Zhang, Z., Wang, Z., Zhu, Z., Li, H., Zeng, W., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102409 · Cited by 2
Genomic correlates of clinical CAR T cell activity
Leick, M. B., Sun, B., Birocchi, F., Gallagher, K., Bratt, A., Han, S., Martin, G. A., Silva, H. J., Larson, R. C., Chinsky, T. M., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.aef4134 · Cited by 2
Rosato, F., Santiago-Sánchez, G. S., Fabian, K. P., Padget, M., Lee, J. K., Allen, C., Su, Z., Katragadda, M., Moisan, J., Bayliffe, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013158 · Cited by 2
Ma, X., Gui, T., Yang, S., Jin, S., Qiao, J., Xie, Y., Wang, J., Ouyang, W., Song, G., Yi, X. H., et al. (2025) · MedScience · doi:10.1007/s11684-025-1176-9 · Cited by 2
CAR T Cell Toxicities and Emerging Treatment Strategies
Lulu, A. M., Steele, E., & Lee, D. W. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050224-120336 · Cited by 3
Dreyzin, A., Gava, F. M., Lamplugh, C., Ma, J., & Silbert, S. K. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201171 · Cited by 2
Zhang, Y. C., Yang, J., Xin, H., Ai, K., Yang, M., Li, Y., & He, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004066 · Cited by 2
Wu, S., Zhou, L., Kang, X., Huang, G., Cha, Y. L., Shen, J., Wang, C., Lackey, K., Kim, D., Dai, S., et al. (2026) · ACS Sensors · doi:10.1021/acssensors.5c04120 · Cited by 2
Ying, H., Pan, Y., Zhu, X., & Xuan, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778197 · Cited by 2
CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity
Lindenbergh, P. L., Giavridis, T., Vivier, O., Lopez, M. A., Dobrin, A., Mack, M., Cohen, J. L., Themeli, M., & Sadelain, M. (2026) · Science Immunology · doi:10.1126/sciimmunol.aea6276 · Cited by 2
Sant’Anna, L. E., Roy, R., Schwab, J. C., Perez, J. I., & Mayalu, M. N. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101716 · Cited by 2
Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma
Perica, K., Palomba, M. L., & Brentjens, R. J. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.23 · Cited by 2
Arya, R. S., Barrett, D. M., Grupp, S. A., & Melenhorst, J. J. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000513 · Cited by 2
Self-citationCurrent Research Trends in Cytokine Storm: A Scientometric Study
Wang, Q., Cui, Y., Wang, K.-T., Xu, D. W., Wang, Y., Dong, X., Tang, J., Wang, Y., Qiao, T., & Zhang, H. (2022) · Current Drug Targets · doi:10.2174/1389450123666220414135249 · Cited by 2
Zhou, L., Yu, N., Li, T., Ji, H., Jiang, L., Wang, D., Xu, B., & Zhou, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.912689 · Cited by 2
Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies
Wang, Y., Sun, R., Ge, W., Xue, L., Xu, Q., Xu, H., Li, S., Wu, M., Guo, T., & Wang, X. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00322 · Cited by 2
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
